As a leader who has committed much of his career to improving healthcare — an industry that holds millions of people’s lives ...

There’s no escaping AI – try as we all did at HLTH – but Brook Health’s plan is to use AI to extend the primary care provider’s relationship to the patient’s home for chronic disease ...

At a time when the healthcare industry is battling point solution fatigue, it begs the question: is there still a place for all these solutions? According to one industry executive —Doba ...

Make no mistake: the hype surrounding generative AI in the healthcare sector is still going strong. Overall, the industry is excited about the technology’s potential to alleviate burnout ...

Novo Nordisk was a pioneer in developing GLP-1 drugs for metabolic disorders, but its products are still mainly once-weekly injections. The Danish pharmaceutical giant is putting up $285 million ...

GLP-1 receptor agonists, like Wegovy and Ozempic, have taken center stage in obesity and diabetes treatment, praised for their ability to curb appetite, reduce “food noise,” and slow digestion ...

Pills that work similarly to currently available injectable medications represent the next wave of metabolic disorder drugs, and Viking Therapeutics is pushing its drug candidate to the forefront ...

In a recent interview, Elizabeth Mitchell, president and CEO of the Purchaser Business Group on Health, discussed employers' ...

Hundreds of digital health startups attended this year’s HLTH conference, which was held last week in Las Vegas. These companies were seeking venture capital, new customers and some fresh ...

Value-based care (VBC) models (which I’ve previously discussed) focus on reducing cost and improving health outcomes for defined “episodes” of care, with the expected cost of these episodes ...

Over decades, antibodies have established themselves as a key therapeutic modality for a wide range of diseases. But antibodies as they are found in nature did not evolve to be used as drugs, says ...